Microcap Ledger Clene Inc. $CLNN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Salt Lake City, UT
- Fiscal year end
- December 31
- Shares outstanding
- 12,848,513 [10-Q 2026-08-14]
What the company doesAI summary of filing
Clene Inc. is a clinical-stage pharmaceutical company that develops catalytically-active gold and other transition metal nanocrystals for treating neurodegenerative diseases including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. The company's lead candidate, CNM-Au8, is an oral suspension of gold nanocrystals designed to improve cellular energy production and reduce oxidative stress. Clene is currently generating no revenue from drug sales but maintains multiple ongoing clinical trials and expanded access programs; the company also generates revenue through dietary supplements marketed under the dOrbital and 4Life brands. The company is pre-revenue from drug products and is in clinical development stages. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $105.0K | −$21.52M | −$7.12M | $9.67M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $200.0K | −$26.17M | −$18.55M | $5.19M | [10-K 2026-03-17] |
| FY ended Dec 2024 | $342.0K | −$39.40M | −$21.33M | $12.15M | [10-K 2026-03-17] |
- Quarterly cash burn
- −$3.56M
- Cash runway Estimate
- ~8.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 7,979,726 | [10-Q 2024-11-13] |
| 2025-03-19 | 8,586,460 | [10-K 2025-03-24] |
| 2025-05-05 | 8,982,747 | [10-Q 2025-05-07] |
| 2025-08-11 | 9,990,568 | [10-Q 2025-08-14] |
| 2025-11-10 | 10,333,980 | [10-Q 2025-11-13] |
| 2026-03-13 | 11,778,307 | [10-K 2026-03-17] |
| 2026-05-11 | 12,778,307 | [10-Q 2026-05-14] |
| 2026-08-11 | 12,848,513 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-09-05; declared effective 2025-09-12 [S-3 2025-09-05]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-16 | Matlin David J | grant | 434,451 | $3.28 | [4 2026-09-18] |
| 2026-09-16 | Etherington Robert Dee | grant | 15,244 | $3.28 | [4 2026-09-18] |
| 2026-09-16 | Mosca Alison | grant | 198,171 | $3.28 | [4 2026-09-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-16 | 8-K | Material agreement entered; Other events |
| 2026-09-16 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-11 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-22 | 8-K | Material agreement entered; Director or officer change; Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $CLNN
Email me when Clene Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.